NTT-DATA
NTT DATA, a global digital business and IT services leader, today announced a new global banking research report entitled "The Digital Horizon: Banking’s Shift from Mainframe to AI-Driven Cloud Infrastructure.” The research has unveiled findings from a survey of 650 global banking decision-makers, marking a definitive shift in the sector towards agile and customer-focused banking. Moreover, the survey uncovers a transformative trend: banks are finally pivoting from entrenched mainframe systems to adopt AI and cloud technologies, spurred by the multiple headwinds they face of consumer demands, innovative new market disruption, and the competitive pressures of innovative technological advancements.
Modernisation and Transformation Trends:
- Enduring Mainframes: Despite 89% of banking leaders identifying as innovators, 63% still operate on mainframe systems, confirming the mainframe’s resilience.
- Cloud Migration to Increase from Generative AI injection: 63% of banking decision-makers confirm generative AI is decisively facilitating the transition of banking applications to the cloud
- Generative AI Gaining Board-Level Support: A resounding 91% report their AI and cloud initiatives are endorsed by the board, signalling strategic prioritisation.
- Navigating Skill Gaps: With 80% lacking a strategic framework for generative AI adoption, the need for upskilling is evident.
- 45% of banks are already integrating generative AI technology into their technology stacks while a further 30% are in the early stages of looking at it.
- Cloud as an Innovation Enabler: Flexibility and scalability are cited by 36% of respondents as key drivers for cloud migration, indicating a shift beyond cost concerns.
The enduring stronghold of mainframes in the banking sector is poised for a significant shift, thanks to the integration of generative AI into cloud migration strategies. NTT DATA's research reveals that 63% of banking decision-makers confirm generative AI is decisively facilitating the transition of banking applications to the cloud, indicating a transformative phase where mainframes’ resilience meets the agility of cloud computing.
25% of respondents also acknowledge a growing trend in cloud migration, propelled by AI advancements. This heralds a new era where the collaboration between AI’s potential to reinterpret legacy code and cloud technology's scalability is accelerating modernisation and transformation initiatives, suggesting that the longstanding reign of mainframes is approaching its horizon.
Kaz Nishihata, Director and Senior Executive Vice President at NTT DATA Group Corporation, commented: "Banks are not only evolving technologically but also culturally. The industry’s rapid adoption of AI and cloud is redefining business models and establishing a new norm in sector leadership. This technological tide is propelling banks toward a more intimate understanding of customer needs, delivering services that are faster, more secure, and uniquely tailored."
The research also found that the banking industry is rapidly embracing the transformative power of generative AI, with 45% of banks already incorporating it into their operations. Additionally, 30% are exploring its potential, signalling a proactive shift towards innovation. This adoption underscores the sector's commitment to future-proofing services and the desire for organisations to enhance their competitive edge in a fast-evolving digital landscape.
Nishihata adds, “The momentum for generative AI across the banking sector is a testament to the industry’s resolve to move beyond traditional mainframes, leveraging cloud environments to fortify security, enhance robustness, innovate, and boldly redefine. This transition promises a new era of innovation.”
To read the full report, visit "The Digital Horizon: Banking’s Shift from Mainframe to AI-Driven Cloud Infrastructure"
About the research
NTT DATA's survey canvasses a diverse array of banking professionals, from all global banking markets, and provides a 360-degree perspective on the sector's modernisation and journey towards innovation and transformation.
Demographics of Respondents:
- Global Insights: Leaders from a broad geographic spectrum, including the United States, the United Kingdom, Japan, Germany, Spain, Italy, Mexico, and Brazil.
- Institutional Scope: A cross-section from multinational banks to local banking institutions.
- Expertise Range: Perspectives across IT, Operations, Innovation, and Strategy.
About NTT DATA
NTT DATA – a part of NTT Group – is a trusted global innovator of IT and business services headquartered in Tokyo. We help clients transform through consulting, industry solutions, business process services, IT modernisation and managed services. NTT DATA enables clients, as well as society, to move confidently into the digital future. We are committed to our clients’ long-term success and combine global reach with local client attention to serve them in over 50 countries. Visit us at nttdata.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240208750914/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
